Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome


Anorexia can affect up to 90 % of people with advanced cancer. It is a complex symptom associated with changes in taste, lack of hunger at mealtimes and lack of food enjoyment. Associated weight loss is part of the physical decline that occurs as cancer worsens. Weight loss can also occur from cachexia, the increased metabolism of energy due to raised inflammatory cytokines, liver metastases and other factors seen in several advanced cancers. Independent of anorexia, although frequently associated (where it is referred to as the cachexia-anorexia syndrome), it accounts for a significant amount of morbidity and deaths in people with cancer. In particular, quality of life for the patient and the family is significantly affected with this syndrome as it causes anxiety and distress. Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population. Cannabinoids are one such group of therapies that have received a large amount of media focus recently. However, there appears to be a lack on rigorous pharmacokinetic data of these complex and varied compounds in the cachexic population. Similarly, there is a lack of pharmacokinetic data in any population group for the non- tetrahydrocannabinol (THC) and cannabidiol (CBD) cannabinoids (often due to the lack of analytical standards for quantification). This review will thus examine the pharmacokinetics of major cannabinoids i.e. THC and CBD in a cancer population. Overall, based on the current literature, evidence for the use of cannabinoids for the treatment of cancer-related cachexia-anorexia syndrome remains equivocal. A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose–concentration and concentration–response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population.

This is a preview of subscription content, log in to check access.


  1. 1.

    Reid J, McKenna H, Fitzsimons D, McCance T. The experience of cancer cachexia: a qualitative study of advanced cancer patients and their family members. Int J Nurs Stud. 2009;46(5):606–16.

    Article  PubMed  Google Scholar 

  2. 2.

    Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med. 2002;16(6):499–506.

    Article  PubMed  Google Scholar 

  3. 3.

    Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18(1):1–9.

    Article  PubMed  Google Scholar 

  4. 4.

    Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23(33):8500–11.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Miller S, McNutt L, McCann MA, McCorry N. Use of corticosteroids for anorexia in palliative medicine: a systematic review. J Palliat Med. 2014;17(4):482–5.

    Article  PubMed  Google Scholar 

  6. 6.

    Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;3:CD004310.

  7. 7.

    Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614–48.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Engeli S. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol. 2012;209:357–81.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Pichard C, Kyle U. Body composition measurements during wasting diseases. Curr Opin Clin Nutr Metab Care. 1998;1(4):357–61.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–804.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology. 1981;74(3):208–12.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52(1):31–41.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Ohlsson A, Widman M, Carlsson S, Ryman T, Strid C. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol (Copenh). 1980;47(4):308–17.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34(3):352–63.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Guy GW, Robson PJ. A phase I, double-blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J Cannabis Ther. 2003;3(4):121–51.

    CAS  Article  Google Scholar 

  17. 17.

    Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66–75.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec. 1971;8(4):391–402.

    CAS  PubMed  Google Scholar 

  19. 19.

    Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther. 1980;215(1):35–44.

    CAS  PubMed  Google Scholar 

  20. 20.

    Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science. 1973;179(4071):391–3.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet. 2015;54(2):209–19.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Trobec K, Kerec Kos M, von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One. 2013;8(11):e79603.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Barry RE. Malignancy, weight loss, and the small intestinal mucosa. Gut. 1074;15(7):562–70.

    Article  Google Scholar 

  25. 25.

    King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25(2):144–9.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Fearon K, Preston T. Body composition in cancer cachexia. Infusionstherapie. 1990;17(Suppl 3):63–6.

    PubMed  Google Scholar 

  27. 27.

    Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–16.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI> or = 27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241–7.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Mouly S, Aymard G, Diquet B, Caulin C, Bergmann JF. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss. J Acquir Immune Defic Syndr. 2000;24(4):344–51.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Cvan Trobec K, Kerec Kos M, Trontelj J, Grabnar I, Tschirner A, Palus S, et al. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6(1):45–52.

  31. 31.

    Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J Gastroenterol Hepatol. 1999;14(10):946–59.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Slaviero K, Clarke SJ, Rivory L. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 2003;4(4):224–32.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retrovir. 1997;13(4):305–15.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust. 1979;2(12):657–9.

    CAS  PubMed  Google Scholar 

  35. 35.

    Regelson W, Butler J, Schulz J, Kirk T, Peek L, Green M. Delta-9-tetrahydrocannabinol (delta-9-THC) as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MS, Szara S, editors. In: Proceedings of an International Conference on the Pharmacology of Cannabis. New York: Raven Press; 1975. p. 269–87.

  36. 36.

    Nelson K, Walsh D, Deeter P, Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10(1):14–8.

    CAS  PubMed  Google Scholar 

  37. 37.

    Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40(3):695–700.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10(2):89–97.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–73.

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24(21):3394–400.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: Department of Palliative Medicine/European Palliative Care Research Collaborative; 2010.

    Google Scholar 

  42. 42.

    Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22(9):2086–93.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Jennifer H. Martin.

Ethics declarations


No funding was provided for this manuscript. Government funding for rigorous clinical trials in medicinal cannabis use have been provided for research projects in New South Wales, Australia.

Conflicts of interest

Jennifer H. Martin and Stephanie E. Reuter are part of the New South Wales Government-funded phase II project team in clinical pharmacology for a study commencing in 2016. Jennifer H. Martin is funded by the University of Newcastle and Calvary Mater Hospital, NSW, Australia, and Stephanie E. Reuter receives funds from the National Health and Medical Research Council, University of South Australia and University of Newcastle.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 140 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reuter, S.E., Martin, J.H. Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. Clin Pharmacokinet 55, 807–812 (2016).

Download citation


  • Cancer Cachexia
  • Cannabidiol
  • Nabilone
  • Dronabinol
  • Cannabis Extract